Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2009
Date:7/14/2009

ody platform with the publication of data in Nature Medicine showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.
  • Entered into a five-year contract potentially worth up to $44.4 million with the Department of Defense's Defense Threat Reduction Agency (DTRA), and ramped up activities under this contract to assess bavituximab and other anti-PS antibodies for biodefense applications against viral hemorrhagic fevers.
  • Continued to enroll and dose patients in an ongoing Phase I clinical trial of bavituximab in hepatitis C virus infected patients co-infected with HIV.
  • Was awarded a U.S. patent that includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids, including PS.
  • Reported that the company's anti-PS technology was positively highlighted in scientific sessions at the AIDS Vaccine 2008 conference in Cape Town, South Africa.
  • Cotara(R) Brain Cancer Program

    • Reported that patient enrollment in the Cotara dosing and dosimetry trial at U.S. brain cancer centers was nearing completion, and that patients in the initial two cohorts of the study have all either met or exceeded the expected median survival time of six months for recurrent glioblastoma multiforme (GBM) patients.
    • Presented data at the Society of Nuclear Medicine 2009 Annual Meeting showing that Cotara specifically localizes to brain tumors at high concentrations with minimal radiation exposure to other organs. This data confirms a key safety attribute of Cotara - its ability to precisely target tumors. Data showed that the concentration of Cotara in brain tumors was on average more than 300-fold higher than in normal organs.
    • Reported that patient enrollment has exceeded the halfway mark in the Cotara Phase II trial in patients with relapsed GBM.
      '/>"/>

    SOURCE Peregrine Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine news :

    1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
    2. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
    3. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
    4. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
    5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
    6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
    7. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
    8. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
    9. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
    10. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
    11. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2014)... 28, 2014 Home Care Assistance ... for seniors, is proud to welcome Carrie Rose as ... Home Care Assistance, Carrie worked as a caregiver in ... Certified Nursing Assistant in skilled nursing facilities for several ... a trainer with the State of Arizona in the ...
    (Date:8/28/2014)... have been adopted by most health agencies to deal ... unnecessary, and may heighten panic and fear among the ... published in The Lancet , and written by ... in Spain, and colleagues. , Ebola virus is ... faeces and other secretions, both direct and indirect, from ...
    (Date:8/28/2014)... become increasingly about datahow to gather it, organize ... databases to analyze and share data lies at ... collection, classification, storage, and analysis of biochemical and ... and methods used in bioinformatics have been instrumental ... genetics and genomics. But, in the plant sciences, ...
    (Date:8/28/2014)... Worth, FL (PRWEB) August 28, 2014 Following ... on July 21, the FDA issued a warning ... the word about this harmful substance that is readily available ... , In May, high school senior Logan Stiner died from ... investigation of the substance, leading the FDA to issue a ...
    (Date:8/28/2014)... researchers place glue directly on the nerve stumps, but ... and allows glue to easily invade the nerve ends. ... to insert the nerve ends into the conduit because ... Xiangdang Liang and co-workers from the General Hospital of ... technique and defined the best parameters for its use ...
    Breaking Medicine News(10 mins):Health News:Home Care Assistance Expands Staff to Meet Growing Demand for In-Home Care Services in Scottsdale 2Health News:Home Care Assistance Expands Staff to Meet Growing Demand for In-Home Care Services in Scottsdale 3Health News:The Lancet: Respiratory infection controls being used for ebola patients are unnecessary and may contribute to public panic 2Health News:Together, humans and computers can figure out the plant world 2Health News:Together, humans and computers can figure out the plant world 3Health News:FDA Issues Safety Advisory for Caffeine Powders 2
    ... Presents Study at International Society of Cellular Therapy ... Cells for Possible Utilization in TransplantationOLDSMAR, Fla., May ... announced results of a new study showing that ... cells from umbilical cord blood expands the number ...
    ... N.Y., May 5 Nutrition 21, Inc. (Nasdaq: ... help consumers manage blood sugar levels, improve cardiovascular health, enhance ... - prior to the opening of the market - on ... year 2009, ended March 31, 2009. The Company has scheduled ...
    ... 5 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex" or the ... independent American,provider of Western healthcare products and services ... the Company is scheduled to participate in the,Oppenheimer ... 19-21, 2009, at,300 Madison Avenue in New York ...
    ... Assists Physicians In Identifying Recurrence Risk and the Need ... Clarient, Inc. (Nasdaq: CLRT ... resource for pathologists, oncologists and the pharmaceutical industry, today ... test that helps physicians identify the probability of a ...
    ... It,s official...Curamin is the natural products industry,s Best ... number-one pain-relieving product, is slated to receive a ... magazine in its upcoming June issue. The ... based on a nationwide survey of health food ...
    ... medical supplies on a regular basis can save even more with ... many struggle with rising medical costs, the MSD Club membership will ... incontinence and other disposable medical supplies. , ... (PRWEB) ...
    Cached Medicine News:Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 2Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 3Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 4Health News:Menstrual Blood Stem Cells May Significantly Increase Yield of Cord Blood Stem Cells 5Health News:Nutrition 21 to Report Third Quarter Fiscal Year 2009 Financial Results on Tuesday, May 12, 2009 2Health News:Chindex International, Inc. Announces May Conference Participation 2Health News:Clarient Launches New Breast Cancer Test 2Health News:Clarient Launches New Breast Cancer Test 3Health News:Clarient Launches New Breast Cancer Test 4Health News:Clarient Launches New Breast Cancer Test 5Health News:Clarient Launches New Breast Cancer Test 6Health News:Curamin Voted Best New Natural Remedy in the Country 2Health News:TheMedicalSupplyDepot.com Announces New Discount Medical Supplies MSD Club 2
    (Date:8/28/2014)... , August 28, 2014 ... Market Research "Radiofrequency Identification (RFID) Market (Tags, Readers, Middleware, ... Growth, Trends and Forecast, 2014 - 2020" the global ... billion in 2013 and is expected to grow at ... reach an estimated value of USD 5.3 billion in ...
    (Date:8/28/2014)... 28, 2014   Venaxis, Inc.  (Nasdaq:  APPY), an ... FDA clearance for and commercializing its CE Marked ... in identifying children, adolescent, and young adult patients in ... appendicitis, today announced it will present at three upcoming ... Annual Global Investment Conference being held in ...
    (Date:8/28/2014)... 2014 Telik, Inc. (OTCQB: TELK), a ... with MabVax Therapeutics, Inc. on July 8, 2014, ... to the development of its lead antibody program ... the Company,s internally developed antibody discovery platform.  These ... antibody based therapeutic and diagnostic products based on ...
    Breaking Medicine Technology:Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4
    ... traits contribute to risk, of skin cancer; findings will ... May 18 In two papers published,today, deCODE scientists ... the company,s recent findings in the genetics of pigmentation,traits ... of these,common variants also confer risk of two types ...
    ... Annual Meeting Will Further Demonstrate, the Strength ... CAMBRIDGE, Mass., May 16 Millennium Pharmaceuticals,The Takeda Oncology ... are scheduled to be featured at the 2008 American ... May 30 -,June 3, 2008. The data will highlight ...
    Cached Medicine Technology:deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 2deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 3deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8
    Used for the introduction of catheters, balloons and other vascular devices....
    Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
    Sheath Introducer featuring patented SLIX Valve, rotating collar, kink-resistant cannula and atraumatic tip transitions....
    The TAXUS Express Paclitaxel-Eluting Coronary Stent System is indicated for improving luminal diameter for the treatment of de novo lesions = 28 mm in length in native coronary arteries = 2.5 to = 3....
    Medicine Products: